Utilization of a Novel kLa Measurement Procedure for Bioreactor Characterization and Optimization to Assist with Compliance of Regulatory Guidelines

By ZETA

CGMP regulations stipulate that sampling and testing of in-process materials and drug products requires control procedures to “be established to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product”.

According to USFDA guidelines, utilizing validated processes is critical to ensuring a drug is fit for its intended use.

Please download this free white paper to read more.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.